Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 12:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chemotherapy Induced Peripheral Neuropathy Clear all
Terminated Phase 2 Interventional Results available

The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

NCT01655823
View directory record Official record
Conditions
Pain, Peripheral Neuropathy, Neuropathic Pain
Interventions
Placebo, Tetrodotoxin
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00489411
View directory record Official record
Conditions
Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
475
States / cities
Antioch, California • Berkeley, California • Burlingame, California + 328 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Jun 10, 2026, 12:14 PM EDT
Recruiting Early Phase 1 Interventional

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

NCT07167446
View directory record Official record
Conditions
Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy
Interventions
Cannabidiol (CBD), oxaliplatin-based chemotherapy
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Not applicable Interventional

Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled Study

NCT03824860
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Yoga, Chronic Pain, Neuropathic Pain
Interventions
Yoga
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Not applicable Interventional

Central Mechanisms of Calmare: an fMRI Trial

NCT04242797
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Calmare, TENS
Device
Lead sponsor
Brigham Young University
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Provo, Utah
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Jun 10, 2026, 12:14 PM EDT
Terminated No phase listed Observational

Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage

NCT01293851
View directory record Official record
Conditions
Peripheral Neuropathic Pain, Neurotoxicity, Cancer
Interventions
Not listed
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Jun 10, 2026, 12:14 PM EDT
Recruiting Not applicable Interventional

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

NCT06162403
View directory record Official record
Conditions
Peripheral Nerve Stimulation, Chemotherapy-induced Peripheral Neuropathy
Interventions
Peripheral Nerve Stimulation
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 10, 2026, 12:14 PM EDT
Enrolling by invitation Not applicable Interventional

Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device

NCT07061769
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN), Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Neuropathic Pain
Interventions
SHIFT
Device
Lead sponsor
FluxWear, INC
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 10, 2026, 12:14 PM EDT
Active, not recruiting Phase 2 Interventional

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

NCT06568042
View directory record Official record
Conditions
Neuropathic Pain, Distal Sensory Polyneuropathy
Interventions
LY3848575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Chandler, Arizona • Phoenix, Arizona • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Not applicable Interventional

Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy

NCT05374876
View directory record Official record
Conditions
Adenocarcinoma of Pancreas
Interventions
Hand Therapy Until CIPN
Other
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Not applicable Interventional

Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT01006408
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Low Level Laser, Placebo followed by Low Level Laser
Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Early Phase 1 Interventional

Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

NCT03943498
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Numbness, Pain, Tingling
Interventions
Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Not applicable Interventional Results available

Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy

NCT02000908
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
photobiomodulation, Sham treatment, Physiotherapy
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Phase 2 Interventional

Using Game-based Exercise to Improve Balance in Cancer Patients

NCT02773329
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy, Cancer
Interventions
sensor-based interactive exercise (game-based exercise), Intervention without game-based exercise
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
55 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jun 10, 2026, 12:14 PM EDT
Not yet recruiting No phase listed Observational

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

NCT07499882
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
Ziconotide
Drug
Lead sponsor
Christian Hospital Northeast Northwest
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 10, 2026, 12:14 PM EDT
Terminated Not applicable Interventional

Auricular Point Acupressure: Examining the Scientific Underpinnings of Pain Relief

NCT03634527
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Interventions
Auricular Point Acupressure, Control Auricular Point Acupressure-
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jun 10, 2026, 12:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy

NCT05488873
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
WST-057 Active, Placebo
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Jun 10, 2026, 12:14 PM EDT
Completed No phase listed Observational

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT03709888
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Memantine XR-pregabalin combination therapy
Drug
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Phase 3 Interventional

Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

NCT00058071
View directory record Official record
Conditions
Gestational Trophoblastic Tumor, Neurotoxicity, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
57
States / cities
Burbank, California • La Jolla, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Jun 10, 2026, 12:14 PM EDT
Active, not recruiting Not applicable Interventional

Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

NCT06121232
View directory record Official record
Conditions
Neuropathy;Peripheral
Interventions
Abbott® DRG / Abbott®/Medtronic® SCS, Control Group
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Not applicable Interventional Results available

A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)

NCT03687970
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Brief Pain Inventory, Hospital Anxiety and Depression Scale, Neuropathic Pain Symptom Inventory, Diode Laser fiber type Selective Stimulator, Quantitative sensory testing, Conditioned pain modulation efficiency, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)
Other · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Not applicable Interventional

Acupuncture for Symptoms of Nerve Damage

NCT03183037
View directory record Official record
Conditions
Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy
Interventions
Acupuncture, Sham Acupuncture, Usual Care Group, questionnaires
Procedure · Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jun 10, 2026, 12:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT04001829
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Docetaxel, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
485
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 10, 2026, 12:14 PM EDT
Completed Not applicable Interventional

Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy

NCT03195868
View directory record Official record
Conditions
Neuropathy, Neuropathy, Diabetic, Neuropathy Toxic
Interventions
Realief Therapy
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Jun 10, 2026, 12:14 PM EDT